EFSD/Sanofi European Diabetes Research Programme: Innovative Approaches for the Treatment of Type 1 and Type 2 Diabetes


Jean-S├Ębastien Annicotte: University of Lille 2 - France
Modulating KAT2B activity in mouse and human pancreatic islets as a new approach for the treatment of type 2 diabetes

Zheng-Liang Zhi: King’s College London - UK
Direct display of immunomodulatory agents on islets by nanocoating as a means of improving transplantation outcomes


Paolo Fiorina: San Raffaele Scientific Institute - Milan, Italy
PD-L1+ hematopoietic stem cells: a novel stem cell-based approach for type 1 diabetes

Chantal Mathieu: Catholic University Leuven - Belgium
Actobiotics™-based strategies in type 1 diabetes: from bench-to-bedside translation 

Eran Segal: Weizmann Institute of Science - Rehovot, Israel
Testing the efficacy of personally tailored low-glycaemic diets derived using microbiota information 


Sylvie Guerder: The Physiopathology Center of Toulouse Purpan - France
TSSP a potential therapeutic target to control autoimmune diabetes: functional analysis in humans

Pedro Herrera: University of Geneva - Switzerland
Factors driving alpha cells into insulin production: towards a new treatment for diabetes

Nigel Irwin: University of Ulster - UK
A chemically modified analogue of the gut peptide xenin and its potential to restore GIP action in type 2 diabetes

Nina Kaludercic: National Reserach Council - Padova, Israel
Monoamine oxidase inhibition as a new therapeutic strategy for the treatment of diabetic cardiomyopathy

Yossef Tam: The Hebrew University of Jerusalem - Switzerland
Targeting proximial tubular cannabinoid type-1 receptor for the treatment of diabetic nephropathy